DMKPQ (DMK Pharmaceuticals) Days Payable: 2,880.45 (As of Sep. 2023)


DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Days Payable?

DMK Pharmaceuticals DMKPQ -99.00% 16 Days Payable is 2,880.45 as of Sep. 2023. GuruFocus rates DMKPQ with a GF Score™ of 16/100.

DMK Pharmaceuticals's average Accounts Payable for the three months ended in Sep. 2023 was $10.67 Mil. DMK Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.34 Mil. Hence, DMK Pharmaceuticals's Days Payable for the three months ended in Sep. 2023 was 2,880.45.

The historical rank and industry rank for DMK Pharmaceuticals's Days Payable or its related term are showing as below:

DMKPQ's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.98
* Ranked among companies with meaningful Days Payable only.

DMK Pharmaceuticals's Days Payable increased from Sep. 2022 (271.73) to Sep. 2023 (2,880.45). It may suggest that DMK Pharmaceuticals delayed paying its suppliers.

DMK Pharmaceuticals Days Payable Historical Data

* Premium members only.

The historical data trend for DMK Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Days Payable Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132.06 99.50 174.45 146.97 344.85

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 271.73 243.29 452.12 2,672.66 2,880.45

DMKPQ vs CNNC, THCT, VFRM: Days Payable Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMK Pharmaceuticals Days Payable vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Days Payable falls into.


DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

DMK Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

Days Payable (A: Dec. 2022 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2021 ) + Accounts Payable (A: Dec. 2022 )) / count ) / Cost of Goods Sold (A: Dec. 2022 )*Days in Period
=( (3.754 + 7.937) / 2 ) / 6.187*365
=5.8455 / 6.187*365
=344.85

DMK Pharmaceuticals's Days Payable for the quarter that ended in Sep. 2023 is calculated as:

Days Payable (Q: Sep. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2023 ) + Accounts Payable (Q: Sep. 2023 )) / count ) / Cost of Goods Sold (Q: Sep. 2023 )*Days in Period
=( (11.366 + 9.973) / 2 ) / 0.338*365 / 4
=10.6695 / 0.338*365 / 4
=2,880.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 2,880.45 mean?
DMK Pharmaceuticals (DMKPQ) has a Days Payable of 2,880.45 as of Sep. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' Days Payable too high?
DMK Pharmaceuticals' current Days Payable is 2,880.45. The Drug Manufacturers industry median Days Payable is 90.98. DMK Pharmaceuticals' value of 2,880.45 is 3066% above this industry median. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' Days Payable compare to CNNC and THCT?
DMK Pharmaceuticals' Days Payable of 2,880.45 can be compared against companies in the Drug Manufacturers industry. The industry median Days Payable is 90.98. DMK Pharmaceuticals' value of 2,880.45 is 3066% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DMK Pharmaceuticals's current Days Payable of 2,880.45 is 3066% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DMK Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DMK Pharmaceuticals's current Days Payable is 2,880.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current Days Payable of 2,880.45. The current Days Payable is 2,880.45 and 3066% above the Drug Manufacturers industry median of 90.98. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current Days Payable is 2,880.45 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price